Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study.
Abstract: Using the 2% detection threshold, individual DRMs with the highest prevalence were: PI M46IL (5.5%), RT K103NS (3.5%), RT G190ASE (3.1%), T215ISCDVEN (2.5%), RT M41L (2.2%), RT K219QENR (1.7%) and PI D30N (1.6%).
Result: Conversely, resistance to efavirenz is mainly predicted by the K103NS mutations.
Result: For example, K103NS was t
High Detection Rate of HIV Drug Resistance Mutations among Patients Who Fail Combined Antiretroviral Therapy in Manaus, Brazil.
Result: In regard to NNRTI, high ARV resistance level was detected in approximately 90.0% of them, representing 64 of those 71 individuals who were taking EFV, and mutations K103N/S (71.8) and P225H (21.1%) were the most prevalent among them.
Result: The most frequently detected DRMs were M184I/V (68/82; 82.9%), K70E/R (16/82; 19.5%), and T215F/Y (17/82; 20.7%) to NRTI and K103N/S (51/82; 62.1%), P225H (15/82; 18.2%), and V106A/I/M (11/82; 13.4%) to NNRTI (Figure 1).
Result: While analyzing the resistance profile of individuals with BCAR and BPAN vari
Transmitted drug resistance and transmission clusters among HIV-1 treatment-naive patients in Guangdong, China: a cross-sectional study.
Discussion: The most frequent NNRTI-associated SDRM in our study was K103N, while it is V179E and V106I in Southwest China and K103N/S and E138A in Iceland and the south-central United States.
Correlation of HIV-1 drug resistant mutations and virologic failure.
PMID: 34584606
2021
The Pan African medical journal
Introduction: These mutations included M184V, K65R,D67N,K70R,K219Q,Q151M, T215F, M41L, T69N, V75M, M41L, T69N, V75M, D67G, V75M, M184I, T215N, M41LM, T215N, K219N,210W, T215Y as NRT
Table: K103S
HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial.
PMID: 34762770
2021
Journal of the International AIDS Society
Abstract: Overall, 18/168 (11%) had NNRTI mutations including K101E, K103N/S, V106M, V108I, E138A/G, V179D/I/T and
Result: Major NNRTI mutations detected included K101E, K103N, K103S, V106M, V108I, E138A/G, V179D/I/T and H221Y, but the frequency of detection of each of these mutations did not differ by arm (Table 1).
Table: K103S
Molecular Network Analysis Reveals Transmission of HIV-1 Drug-Resistant Strains Among Newly Diagnosed HIV-1 Infections in a Moderately HIV Endemic City in China.
Discussion: Because of the low genetic barrier of NNRTI drugs, K103N/S is the predominant mutation in all countries reporting HIVDR data according to the WHO and a study conducted in China.
HIV Pretreatment Drug Resistance Trends in Mexico City, 2017-2020.
Result: Resistance to efavirenz/nevirapine was associated with transmission of K103NS alone in 7.9% (65/820) of clusters, K103NS plus other NNRTI mutations in 3.4% (28/820) clusters and with other NNRTI mutations in 8.0% (66/820) of clusters (Figure 5).
Result: Some examples of the larger clusters evidencing NNRTI PDR transmission included cluster NNRTI-1, with 14 nodes, all men living in Mexico City with median age 28 years (IQR 23-31), all of them with K103NS; cluster NNRTI-2, with 27 nodes formed by men with median age 25 (23-30) enrolled across the complete study period, 11% (3/27) with K103NS and 74% (20/27) with other mutations;
Rapid HIV-1 drug resistance testing in a resource limited setting: the Pan Degenerate Amplification and Adaptation assay (PANDAA).
PMID: 34795836
2021
The Pan African medical journal
Abstract: The performance of the PANDAA assay in screening K65R, K103NS, M184VI, Y181C, and G190A mutations compared to the reference assay, Sanger sequencing was evaluated by Cohen s kappa coefficient on Stata version 14 (StataCorp LP, College Station, TX, USA).
Abstract: We assessed the performance of a rapid HIV-1 drug resistance assay, the Pan Degenerate Amplification and Adaptation (PANDAA) assay when screening for significant HIV-1 drug resistance mutations (DRMs) such as K65R, K103NS, M184VI, Y181C and G190A.
Introduction: Briefly, the PANDAA assay is an allelic discrimination test designed with different
HIV-1 reverse transcriptase and protease mutations for drug-resistance detection among treatment-experienced and naive HIV-infected individuals.
Abstract: M46I and I47V were the most common mutations for PIs, M184V was the most common mutation for the NRTIs, and K103N/S was the most common mutation for NNRTIs.
Result: The most common mutations were M46I and I47V for PIs, M184V for NRTIs, and K103N/S for NNRTIs (Table 6).
Table: K103N/S
Discussion: M46I and I47V were the most frequent mutations for
Natural polymorphisms in HIV-1 CRF01_AE strain and profile of acquired drug resistance mutations in a long-term combination treatment cohort in northeastern China.
Result: The NNRTI-associated DRMs detected at TF time point included G190S/C (66.7%), K101E/N/Q (52.4%), V179D/I/A/T/E (45.2%), Y181C (42.9%), K103R/N/S (42.9%), and V106 M (23.8%) (Table 1).
HIV mutation literature information.
PMID: 
2021
HIV medicine
Browser Board
Co-occurred Entities
Filtrator
ViMRT